All lobbying filings

FEROX STRATEGIES

FEROX STRATEGIES filed a Q4 report for ALEXION PHARMACEUTICALS, INC. on January 20, 2026, reporting $60,000 in lobbying income.

Lobbying for ALEXION PHARMACEUTICALS, INC. · Rare Disease Pharmaceutical company.

All filings by FEROX STRATEGIES · Everything ALEXION PHARMACEUTICALS, INC. has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Issues related to rare disease pharmaceuticals, Orphan Cures H.R. 946, and Pediatric Priority Review Voucher.

Bills named in this filing 1

H.R. 946
ORPHAN Cures Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.